Compare Mesoblast Limited (MESO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Orion Office REIT Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Orion Office REIT Inc trades at $2.68 (market cap $150.60M). The key difference: Mesoblast Limited is far larger — about 14.4× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.02% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | ONL | |
|---|---|---|
Market Cap | $2.17B | $150.60M |
Sector | Technology | Real Estate |
52-Week High | $20.96 | $3.04 |
52-Week Low | $12.88 | $1.93 |
Enterprise Value | $2.17B | $634.25M |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
ONL trades at $2.65, up 0.76% today, with a bullish technical signal despite bearish moving averages. The company reported Q1 2026 earnings with a net loss of $0.24 per share, missing estimates, while revenue declined to $147.65 million in 2025. A strategic review is underway with Wells Fargo and JPMorgan, focusing on portfolio repositioning and debt management, as highlighted in recent earnings calls (MarketBeat, 2026-05-14).
Outlook remains challenging due to persistent losses and high leverage, but the strategic shift toward dedicated-use assets and resolved refinancing risks offer potential upside. Investors face significant execution and market headwinds, with analyst consensus split evenly between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
